Skip to content
Insider tapeFilings through Fri, Nov 20
My stocks

Charles River Laboratories (CRL) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDiagnostics & ResearchCRL

Closing price · Nov 20, 2026 $314.32 -4.2% on the day · +93.9% over 12 months 52-week range $149.93 – $376.10
Get CRL alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling7last 12 months
Reported sales$52.1M10 of 22 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Feb 2, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale James C. Foster, Director sold 24,042 shares at $350.00 ($8.4M).

Trade date
Oct 22, 2026
Disclosed to the SEC
Oct 26, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All CRL insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

CRL insider transactions (Form 4)

Open-market purchases and sales. 97 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Oct 26SEC James C. FosterDirector Sell Plan 24,04231,596 held (−43%) $350.00 $8.4M -10.2% —
Oct 23SEC Shannon M. ParisottoCevp, Disc & Safety Assessment Sell Plan 2,1564,807 held (−31%) $344.41 $743K -8.7% —
Oct 7SEC Shannon M. ParisottoCevp, Disc & Safety Assessment Sell Plan 9814,807 held (−17%) $308.44 $303K +1.9% —
Oct 2SEC Glenn ColemanCFOFirst buy Buy 1027,762 held (+0%) $297.43 $3K +5.7% —
Aug 27SEC James C. FosterDirector Sell Plan 33,56131,596 held (−52%) $300.00 $10.1M +4.8% —
Aug 20SEC Shannon M. ParisottoCevp, Disc & Safety Assessment Sell Plan 2,0394,807 held (−30%) $294.12 $600K +6.9% —
Aug 20SEC Nancy C. AndrewsDirector Sell 5731,438 held (−28%) $285.24 $163K +10.2% —
Aug 13SEC Birgit GirshickCEO Sell Plan 6,50036,013 held (−15%) $279.90 $1.8M +12.3% —
Aug 13SEC Shannon M. ParisottoCevp, Disc & Safety Assessment Sell Plan 3,7144,807 held (−44%) $279.66 $1.0M +12.4% —
Aug 11SEC James C. FosterDirector Sell Plan 28,73331,596 held (−48%) $275.00 $7.9M +14.3% —
Aug 10SEC Victoria L. CreamerEvp & Chief People Officer Sell 4,17930,051 held (−12%) $259.16 $1.1M +21.3% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 1,27414,878 held (−8%) $259.07 $330K +21.3% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 1,20512,588 held (−9%) $258.53 $312K +21.6% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 90113,977 held (−6%) $260.63 $235K +20.6% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 81013,167 held (−6%) $261.45 $212K +20.2% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 73611,852 held (−6%) $258.53 $190K +21.6% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 62012,334 held (−5%) $263.94 $164K +19.1% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 48211,852 held (−4%) $265.17 $128K +18.5% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 40413,793 held (−3%) $258.53 $104K +21.6% —
Aug 10SEC Michael Gunnar KnellSvp, Finance And Cao Sell 21312,954 held (−2%) $262.37 $56K +19.8% —
Aug 6SEC Shannon M. ParisottoCevp, Disc & Safety Assessment Sell Plan 5,0464,807 held (−51%) $263.00 $1.3M +19.5% —
Jul 1SEC James C. FosterDirector Sell Plan 75,00031,596 held (−70%) $225.00 $16.9M +39.7% —
Mar 4SEC Joseph W. LaplumeEvp, Corp Strategy & DevelopFirst buy Buy 2527,448 held (+0%) $174.54 $4K +80.1% —
Jan 20SEC Joseph W. LaplumeEvp, Corp Strategy & Develop Sell 40023,716 held (−2%) $163.72 $65K +92.0% —
Historical context

Similar past setups: not applicable. CRL has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with CRL in the Research Lab

CRL has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

CRL closeInsider buyInsider sale
100200300400DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-13EEarnings release filed 2026-02-18EEarnings release filed 2026-05-07EEarnings release filed 2026-08-05EEarnings release filed 2026-11-04Bought $2,974 on 2026-09-30 · Glenn ColemanBought $4,364 on 2026-03-03 · Joseph W. LaplumeSold $163,443 on 2026-08-18 · Nancy C. AndrewsSold $302,580 on 2026-10-05 · Shannon M. ParisottoSold $599,711 on 2026-08-19 · Shannon M. ParisottoSold $742,548 on 2026-10-21 · Shannon M. ParisottoSold $1,327,098 on 2026-08-05 · Shannon M. ParisottoSold $2,813,279 on 2026-08-06 · Michael Gunnar Knell, Victoria L. CreamerSold $2,858,007 on 2026-08-11 · Birgit Girshick, Shannon M. ParisottoSold $7,901,575 on 2026-08-10 · James C. FosterSold $8,414,700 on 2026-10-22 · James C. FosterSold $10,068,300 on 2026-08-25 · James C. FosterSold $16,875,000 on 2026-06-29 · James C. Foster
Bought, 12 months$0
Sold, 12 months$52.1M
Insiders buying0
Insiders selling7

Charles River Laboratories insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $52.1M of CRL stock on the open market; P/E 363.8 vs. a sector median of 24.5.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

CRL insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q3 2025: $65K sold (1 trades)Q3 2025Q4 2025Q1 2026: $4K bought (1 trades)$4KQ1 2026Q2 2026: $16.9M sold (1 trades)Q2 2026Q3 2026: $3K bought (1 trades)$3KQ3 2026: $25.7M sold (17 trades)Q3 2026Q4 2026: $9.5M sold (3 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$9.5M3
Q3 2026$3K1$25.7M17
Q2 2026—0$16.9M1
Q1 2026$4K1—0
Q4 2025—0—0
Q3 2025—0$65K1

Valuation, profit and volume

P/E (trailing)363.8Sector median 24.5
Market value$16.04BDiagnostics & Research
Profit margin1.0%Revenue growth -2.2%
Volume vs. 50-day0.6×Last 5 sessions
Insiders' paper profit+$4KOn all tracked purchases +49.9%

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Charles River Laboratories insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $52.1M. 10 of 22 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

CRL earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Nov 4, 2026 +17.3% Sold $9.5M -11.0%S&P -2.8% pending
Aug 5, 2026 +6.6% None +13.4%S&P -0.4% +8.7%
May 7, 2026 -0.7% None -2.3%S&P +0.5% +2.1%
Feb 18, 2026 -25.6% None +3.6%S&P +0.2% -6.5%
Jan 13, 2026 +7.4% None -1.1%S&P -0.7% -25.4%
Nov 5, 2025 -3.4% None -3.9%S&P -0.7% +7.9%
Aug 6, 2025 +11.8% None -10.6%S&P +0.7% +9.5%
May 7, 2025 +12.4% None +22.5%S&P +1.1% +2.4%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

CRL news sentiment trend

Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.

Not enough news
Aug 22Week of 2026-09-05: 2 headlines, 0 positive, 0 negativeSep 12Week of 2026-09-19: 5 headlines, 1 positive, 0 negativeWeek of 2026-09-26: 2 headlines, 0 positive, 0 negativeInsider buying that weekWeek of 2026-10-03: 1 headlines, 0 positive, 0 negativeOct 3Oct 24Nov 14
Last 30 days: 0 headlines, 0 positive, 0 negative

Tone is scored from headline wording only. It describes the news, not where the stock is going.

CRL short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-28: 44% of volume sold short2026-08-31: 21% of volume sold short2026-09-01: 31% of volume sold short2026-09-02: 29% of volume sold short2026-09-03: 50% of volume sold short2026-09-04: 44% of volume sold short2026-09-08: 44% of volume sold short2026-09-09: 41% of volume sold short2026-09-10: 29% of volume sold short2026-09-11: 40% of volume sold short2026-09-14: 52% of volume sold short2026-09-15: 52% of volume sold short2026-09-16: 56% of volume sold short2026-09-17: 57% of volume sold short2026-09-18: 56% of volume sold short2026-09-21: 48% of volume sold short2026-09-22: 59% of volume sold short2026-09-23: 56% of volume sold short2026-09-24: 62% of volume sold short2026-09-25: 54% of volume sold short2026-09-28: 63% of volume sold short2026-09-29: 70% of volume sold short2026-09-30: 64% of volume sold short2026-10-01: 59% of volume sold short2026-10-02: 58% of volume sold short2026-10-05: 67% of volume sold short2026-10-06: 74% of volume sold short2026-10-07: 67% of volume sold short2026-10-08: 48% of volume sold short2026-10-09: 71% of volume sold short2026-10-12: 56% of volume sold short2026-10-13: 56% of volume sold short2026-10-14: 71% of volume sold short2026-10-15: 63% of volume sold short2026-10-16: 60% of volume sold short2026-10-19: 73% of volume sold short2026-10-20: 81% of volume sold short2026-10-21: 65% of volume sold short2026-10-22: 77% of volume sold short2026-10-23: 63% of volume sold short2026-10-26: 64% of volume sold short2026-10-27: 44% of volume sold short2026-10-28: 56% of volume sold short2026-10-29: 52% of volume sold short2026-10-30: 45% of volume sold short2026-11-02: 33% of volume sold short2026-11-03: 31% of volume sold short2026-11-04: 33% of volume sold short2026-11-05: 45% of volume sold short2026-11-06: 55% of volume sold short2026-11-09: 58% of volume sold short2026-11-10: 46% of volume sold short2026-11-11: 65% of volume sold short2026-11-12: 47% of volume sold short2026-11-13: 58% of volume sold short2026-11-16: 59% of volume sold short2026-11-17: 55% of volume sold short2026-11-18: 56% of volume sold short2026-11-19: 49% of volume sold short2026-11-20: 49% of volume sold shortAug 28Sep 14Sep 28Oct 12Oct 26Nov 9
Latest (Nov 20): 49%20-day average: 47%Prior 2 months: 58%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

CRL stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insiders at Charles River Laboratories

InsiderBoughtSoldLast filingPast buys beat S&PScore
James C. FosterDirector — $43.3M Oct 26, 2026 1 of 2 —
Shannon M. ParisottoCevp, Disc & Safety Assessment — $4.0M Oct 23, 2026 — —
Birgit GirshickCEO — $1.8M Aug 20, 2026 1 of 2 —
Michael Gunnar KnellSvp, Finance And Cao — $1.7M Nov 9, 2026 — —
Victoria L. CreamerEvp & Chief People Officer — $1.1M Aug 10, 2026 — —
Nancy C. AndrewsDirector — $163K Aug 20, 2026 — —
Joseph W. LaplumeEvp, Corp Strategy & Develop $4K $65K Aug 11, 2026 — —
Glenn ColemanCFO $3K — Oct 2, 2026 — —
Steven BargDirector — — Jun 3, 2026 — —
Mark MintzEvp, Chief Information Officer — — Jun 2, 2026 — —
Paul W. GravesDirector — — May 12, 2026 — —
Craig B. ThompsonDirector — — May 12, 2026 — —
Virginia M. WilsonDirector — — May 11, 2026 — —
Reshema Kemps-PolancoDirector — — May 11, 2026 — —
Mark J. EnyedyDirector — — May 11, 2026 — —
George Llado Sr.Director — — May 11, 2026 — —
Martin MacKayDirector — — May 11, 2026 — —
Abraham CeesayDirector — — May 11, 2026 — —

Board links: companies that share insiders with CRL

Directors and executives who filed Form 4s for CRL and another company in the last 12 months.

See the map →
  • RAPPRapport Therapeutics Abraham Ceesay Director here · CEO at RAPP · latest filing Oct 23, 2026
  • REGNRegeneron Pharmaceuticals Craig B. Thompson Director here · Director at REGN · latest filing May 12, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

CRL stock: common questions

Are Charles River Laboratories insiders buying CRL stock?

No. No Charles River Laboratories insider reported an open-market purchase of CRL in the past 12 months. The latest was CFO Glenn Coleman bought $3K of CRL at $297.43 — first open-market purchase in our records.

Are Charles River Laboratories insiders selling CRL stock?

7 insiders reported sales worth $52.1M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is CRL's P/E ratio?

CRL trades at about 363.8 times trailing earnings, compared with a median of 24.5 for the Health Care sector.

What is CRL's 52-week range?

Over the past year CRL has traded between $149.93 and $376.10. It last closed at $314.32 on Nov 20, 2026.